Skip to main content
padlock icon - secure page this page is secure

ZnO Nanoparticles Induces Cell Death in Malignant Human T98G Gliomas, KB and Non-Malignant HEK Cells

Buy Article:

$106.34 + tax (Refund Policy)

This paper reports the synthesis and characterization of ZnO nanoparticles prepared by soft chemical process. The nanoparticles of ZnO possess wurtzite hexagonal phase and were used for the induction of cell death in malignant human T98G gliomas, KB epithermoids and HEK normal non-malignant kidney cells. By applying ZnO nanoparticles, the cells exhibit that the nanoparticles are more efficacious on T98G cancer cells, moderately effective on KB cells and least toxic on normal human HEK cells. The results demonstrated that the treatment with ZnO nanoparticles sensitize T98G cells by increasing both the mitotic (linked to cytogenetic damage) and interphase (apoptosis) death. The ZnO nanoparticles behave as genotoxic drugs, since they induce a micronucleus formation in cells. The present study could be helpful in designing more potent anticancer agents for the therapeutic uses.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: HEK CELLS; HUMAN T98G GLIOMAS; KB EPITHERMOIDS CANCER; ZNO NANOPARTICLES

Document Type: Research Article

Publication date: July 1, 2013

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more